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Reduced Osteoarthritis Severity in Aged Mice With
Deletion of Macrophage Migration Inhibitory Factor
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Objective. Macrophage migration inhibitory factor
(MIF) is a proinflammatory cytokine that is elevated in
the serum and synovial fluid of patients with osteoarthri-
tis (OA). This study was undertaken to investigate the
potential role of MIF in OA in human joint tissues and in
vivo in mice with age-related and surgically induced OA.
Methods. MIF in conditioned media from human
chondrocytes andmeniscal cells and from cartilage explants
was measured by enzyme-linked immunosorbent assay. The
severity of OA was analyzed histologically in male wild-type
andMIF2/2 mice at 12 and 22 months of age and following
destabilization of the medial meniscus (DMM) surgery in
12-week-old MIF2/2 mice as well as in wild-type mice
treated with a neutralizing MIF antibody. Synovial hyper-
plasia was graded in S100A8-immunostained histologic sec-
tions. Bone morphometric parameters were measured by
micro–computed tomography.
Results. Human OA chondrocytes secreted 3-fold
higher levels of MIF than normal chondrocytes, while nor-
mal and OA meniscal cells produced equivalent amounts.
Compared to age- and strain-matched controls, the
cartilage, bone, and synovium in older adult mice with
MIF deletion were protected against changes of naturally
occurring age-related OA. No protection against DMM-
induced OA was seen in young adult MIF2/2 mice or in
wild-type mice treated with anti-MIF. Increased bone den-
sity in 8-week-old mice with MIF deletion was not main-
tained at 12 months.
Conclusion. These results demonstrate a differen-
tial mechanism in the pathogenesis of naturally occur-
ring age-related OA compared to injury-induced OA.
The inhibition of MIF may represent a novel therapeutic
target in the reduction of the severity of age-related OA.
Aging has been well described as a key risk factor
for the development of osteoarthritis (OA) (1). While
aging does not directly cause OA, aging changes in joint
tissues and possibly circulating factors that change with
age increase susceptibility to the development of the dis-
ease. Aging changes are reflected in the cartilage matrix,
including thinning of the articular cartilage (2) and the
accumulation of advanced glycation end products, which
alters the biomechanical properties of the joint (3).
Aging changes are also evident in chondrocytes, where
chondrocytes isolated from older individuals are more
resistant to stimulation with the growth factors insulin-
like growth factor 1 (4,5), transforming growth factor b
(6), and bone morphogenetic protein 6 (7) than chon-
drocytes isolated from younger individuals. Inflamma-
tory mediators have been found to be up-regulated in
aged joint tissues, including interleukin-7 (IL-7) in
chondrocytes and synovial fluid in humans and IL-33,
CXCL13, CCL8, and CCL5 in the mouse knee joint (for
review, see ref. 8). The increased expression of these
inflammatory mediators, which is compounded by aging
changes in the tissues, may contribute to the develop-
ment of OA.
Macrophagemigration inhibitory factor (MIF) is an
inflammatory cytokine that has been studied for its role in
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the immune system. MIF has been shown to function as a
cytokine that signals through the CD74 receptor (9) to
increase neutrophil migration to regions of inflammation
and to promote the innate immune response (10,11). Addi-
tionally, MIF promotes macrophage activation, increasing
phagocytosis and destruction of pathogens (11,12). MIF
has been studied in autoimmune diseases including rheu-
matoid arthritis (RA) and systemic lupus erythematosus
(SLE). It has been shown to promote matrix metallopro-
teinase 1 (MMP-1) and MMP-3 production in synovial
fibroblasts isolated from the knee joints of RA patients
(13) and also has been shown to be significantly elevated in
RA synovial fluid (14). In a more recent study, inhibition of
MIF function either by deletion of MIF, or its receptor,
CD74, was found to reduce the severity of disease in an RA
model by reducing both inflammation and bone erosion
(15). In SLE, the amount of MIF in serum is positively cor-
related with tissue damage (16), and the renal expression of
MIF was shown to be significantly elevated in an SLE-
prone mouse model (17). The level of MIF was noted to be
elevated in the serum and synovial fluid of patients with
knee OA compared to healthy controls (14,18). However,
the potential contribution of MIF to the development of
OAhas not been studied previously.
Recently, MIF2/2 129Sv/C57BL/6 mice were re-
ported to have an increased lifespan compared to wild-
type controls, suggesting a role for MIF in the aging
process (19), although more recent data suggest that this
beneficial effect may be absent on other genetic back-
grounds (Miller RA: unpublished observations). Like OA,
atherosclerosis is a common disease of aging, and inhibition
of MIF has been found to reduce atherosclerosis in a
mouse model of the disease (20), suggesting that MIF may
represent a therapeutic target for age-related disease.
Given the association between aging and OA, we sought to
determine the contribution of MIF to the development of
OA. We found that genetic disruption of MIF decreased
the severity of naturally occurring OA in aged mice but not
in a surgically inducedmodel of OA in younger adult mice.
MATERIALS AND METHODS
Chondrocyte and meniscal cell isolation and culture.
Normal human donor tissue (from both knee and ankle joints)
was obtained from the Gift of Hope Organ and Tissue Donor
Network (Elmhurst, IL) through the Rush University Medical
Center in Chicago, IL. Osteoarthritic tissue was obtained as
surgical waste from total knee replacement surgeries per-
formed in the Department of Orthopaedic Surgery at Wake
Forest Baptist Health and at the University of North Carolina
Hospitals. The use of human tissue was approved by the insti-
tutional review boards at Rush University, Wake Forest
Baptist Health, and the University of North Carolina at Chapel
Hill. All human donor tissue was de-identified before receipt,
and the cartilage and meniscus were processed separately. The
cartilage was dissected away from the subchondral bone in small
flakes and rinsed in serum-free Dulbecco’s modified Eagle’s
medium (DMEM)/F-12 media (Gibco Life Technologies) to
prevent the tissue from drying out. After the excess fat and liga-
mentous tissue were removed, the meniscus was dissected into
small pieces to enable more efficient digestion. Cells were iso-
lated separately from cartilage and meniscus using Pronase and
collagenase digestion as previously described (21). The cells
were cultured in 10% serum DMEM/F-12 media until conflu-
ent. Cultures were serum starved overnight before media
collection.
A 4-mm biopsy punch was used to harvest human carti-
lage explants from the cartilage pieces that had been dissected
away from the subchondral bone. Three explants per donor
were pooled in 1 well and cultured in 10% serum DMEM/F-12
media for ;72 hours. The explants were serum starved for 48
hours before media collection. The explants were digested in
papain, and the DNA content was quantified using a PicoGreen
kit (Life Technologies) as previously described (22).
Experimental animals. The mice used for these stud-
ies were housed and maintained according to the Institutional
Animal Care and Use Committee guidelines at the respective
institutions where each study was performed (The University of
Michigan, Wake Forest School of Medicine, and The University
of North Carolina at Chapel Hill). Knee joints from MIF2/2
and wild-type mice for the aging experiment were from a previ-
ously published study (19). For the surgically induced OA
experiments, the MIF2/2 mouse colony was bred on the 129Sv/
C57BL/6 mixed background. The colony was maintained by het-
erozygous breeding, so the MIF2/2 and wild-type mice used in
this study were age- and strain-matched littermates. The
C57BL/6 mice used in the neutralizing antibody experiment
were purchased directly from The Jackson Laboratory.
Enzyme-linked immunosorbent assay (ELISA). MIFcon-
tent in serum-free conditionedmedia was quantified by solid-phase
ELISA (R&D Systems) according to the manufacturer’s protocol.
Due to the high level ofMIF in the media, themedia samples were
diluted 1:25 in the assay.
MIF immunostaining. Normal and OA human carti-
lage sections were a kind gift from Dr. Martin Lotz (Scripps
Research Institute, La Jolla, CA). Human cartilage sections and
mid-coronal sections from 12-month-old wild-type and MIF2/2
mouse knee joints were immunostained with anti-MIF (Life
Technologies). Sections were deparaffinized and rehydrated in
serial ethanol washes followed by antigen retrieval in citrate
buffer. Sections were first blocked with 3% H2O2 (Fisher Scien-
tific) and then with Protein Block (Dako). The primary antibody
was diluted in antibody diluent (Dako) and incubated on the sec-
tions overnight at 48C. The following day, the sections were incu-
bated with horseradish peroxidase–linked secondary antibody
(Dako) and developed with the diaminobenzidine chromogen
(Dako). The sections were counterstained in Mayer’s hematoxy-
lin (Sigma) and then dehydrated in serial ethanol washes.
Destabilization of themedialmeniscus (DMM)procedure.
DMM was performed in 12-week-old male MIF2/2 and wild-
type mice as previously described (23). This procedure induces
OA by transecting the medial meniscotibial ligament. For the
sham surgery, the joint was opened and visualized, but the
medial meniscotibial ligament was not cut. We randomly
assigned 14–16 mice to each surgical group and to each of the
anti-MIF treatment and control groups (described below).
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The number of mice chosen for the present study was based
on a power calculation using data from a previously published
DMM and sham surgery control experiment from our group
that included 12-week-old male C57BL/6 mice (23) and found
that a sample size of 12 mice per group would provide .80%
power to detect at least a 50% difference in articular cartilage
structure (ACS) scores between groups. After the surgical pro-
cedure, the mice were monitored closely for signs of apparent
pain or adverse effects of the procedure. The mice were main-
tained in normal housing conditions and allowed to exercise
through normal activities. Ten weeks after surgery, mice were
euthanized and the hind limbs were collected in 10% formalin
(Fisher Scientific) for histologic analysis.
In the anti-MIF experiment, a neutralizing murine anti-
MIF IgG1 (clone NIHIIID.9) and isotype control antibody were
purified from ascites fluid using Protein A/G spin columns
(Thermo Scientific). Following isolation, the antibodies were dia-
lyzed overnight in Dulbecco’s phosphate buffered saline (Lonza)
and then filter-concentrated by centrifugation (Millipore). The
antibody concentration was measured by bicinchoninic acid assay
(Thermo Scientific). After DMM surgery, mice were allowed to
recover for 5 days before antibody treatment began. The anti-
bodies were administered by intraperitoneal injection for the
duration of the study at a dosage (20 mg/kg twice per week) pre-
viously shown to neutralize MIF in vivo (24). The mice were
euthanized 10 weeks after surgery, and legs were collected in for-
malin for histologic analysis. Because repeated handling and
injections can cause pain or other adverse effects which would be
reflected by a decrease in food intake, the body weight of each
mouse was monitored throughout the course of the study. All
mice gained weight consistently over the course of the study, and
there was no difference in the average body weights of each
group at any time point during the study (data not shown).
Histology processing and OA grading. The formalin-
fixed mouse hind limbs were transferred to 70% ethanol, and the
excess soft tissue was removed. The samples were decalcified in
19% EDTA (Fisher Scientific), and the intact joints were embed-
ded in paraffin. The joints were sectioned along the coronal
plane at 4 mm. Mid-coronal sections were stained with hematoxy-
lin and eosin (H&E) and scored using the ACS score developed
by McNulty et al (25). This system scores the integrity of the
articular cartilage on a scale of 0–12, where 0 represents normal
healthy cartilage and 12 represents full-thickness loss of the artic-
ular cartilage across more than two-thirds of the surface scored.
Adjacent mid-coronal sections were also stained with Safranin O
and fast green and scored using the Saf-O score developed by
McNulty et al (25). The Saf-O system scores the proteoglycan
content of the articular cartilage on a scale of 0–12, where 0 rep-
resents uniform staining of healthy cartilage and 12 represents
complete loss of staining across more than two-thirds of the sur-
face. The Saf-O score is more sensitive to the mild-to-moderate
lesions that result from the DMM procedure, since it relies on
proteoglycan loss from the matrix versus fibrillation and loss of
cartilage. Therefore, it (rather than the ACS scoring system) was
used to score OA in those experiments. Additional joint mea-
surements were made using the OsteoMeasure histomorphome-
try system (OsteoMetrics) as previously described (25). The
additional parameters measured were articular cartilage area
and thickness, subchondral bone area and thickness, number of
viable chondrocytes, area of chondrocyte necrosis, and calcified
cartilage area and thickness.
Osteophyte assessment. Osteophytes were graded
using a system that was modified from a previously published
study (26). Osteophytes were graded on a scale of 0–3,
where 05 no osteophyte, 15 questionable/borderline osteo-
phyte, 2 5 small osteophyte, and 3 5 large osteophyte. The
summed osteophyte scores for the medial tibial plateau and
the medial femoral condyle are presented.
Synovial assessment. Coronal sections were immuno-
stained with anti-S100A8 (kindly provided by Dr. Johannes Roth,
Institute of Immunology, University of Munster, Munster,
Germany), which has been used as a method to detect synovitis
with synovial hyperplasia in mouse joints with OA (27). Immuno-
histochemistry was performed as described above except that pro-
teinase K was used for antigen retrieval. Synovial hyperplasia was
graded on a single mid-coronal section from each mouse using a
scale of 0–3 as follows: 05 1–3 cell layers in synovium, 15 4–6
cell layers, 25 7–9 cell layers, and 35 10 or more cell layers. The
medial and lateral compartments of the joint were scored sepa-
rately, and the sum of the 2 scores is presented.
Micro–computed tomography (micro-CT) analysis.
The knee joints from 8-week-old male MIF2/2 mice and wild-
typemice (n5 3 per group) and 12-month-oldmaleMIF2/2mice
(n5 4) and wild-type mice (n5 5) were scanned at 10 mm resolu-
tion bymicro-CT (mct80; ScancoMedical) as previously described
(28). Bone morphometric parameters were measured in the tra-
becular bone of the proximal metaphysis of the tibia using Scanco
software. The region of interest was consistently defined to begin
inferior to the growth plate and extended for 1.00 mm distally.
Bone image data were rotated as necessary to adjust for any verti-
cal alignments. The following histomorphometric trabecular bone
parameters (29) were analyzed using the same threshold for each
animal: bone volume fraction, tissue mineral density, connectivity
density, trabecular number, trabecular separation, and trabecular
thickness.
Statistical analysis. All statistical analyses were per-
formed using GraphPad Prism 6 with one exception. OA histo-
morphometry measurements were analyzed using SPSS, as noted.
Data are presented graphically as individual data points with hori-
zontal lines representing the mean of each group. MIF ELISA
samples were collected frommonolayer cultures of cells or explant
cultures from unique human tissue donors (n5 7–16 donors per
group) and analyzed by unpaired t-test within each tissue type.
OA severity (ACS and Saf-O scores) in individual mice (n5 13–
16 mice per group) was analyzed by Kruskal-Wallis nonparamet-
ric one-way analysis of variance (ANOVA) followed by Dunn’s
multiple comparison test. Histomorphometric measurements
were analyzed by heteroscedastic t-test. Synovial hyperplasia was
evaluated in a subset of mice from the 12-month-old and 22-
month-old groups (n5 5–11 mice per group) and analyzed by
Kruskal-Wallis nonparametric one-way ANOVA followed by
Dunn’s multiple comparison test. Bone parameters were mea-
sured in individual mice (n5 3–5 mice per group) and analyzed
by two-way ANOVA followed by Tukey’s multiple comparison
post hoc test.
RESULTS
Secretion of higher levels of MIF by human OA
chondrocytes than normal chondrocytes. Due to previ-
ously published results showing that MIF is present at
higher levels in OA synovial fluid than in normal synovial
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fluid (14,18), the amount of MIF secreted by joint tissue
cells was measured to determine which tissues could be a
source ofMIF within the joint. Conditionedmedia samples
were collected from unstimulated monolayer cultures of
chondrocytes and meniscal cells and from unstimulated
cartilage explant cultures, and the MIF protein level in the
media was measured by ELISA (Figures 1A and B). Chon-
drocytes isolated from OA cartilage secreted a mean6 SD
of 88.766 13.14 ng/ml ofMIF over 16 hours, which was sig-
nificantly higher (P5 0.0005) than that produced by chon-
drocytes from normal cartilage, which secreted a mean6
SD of 28.236 7.78 ng/ml of MIF. Cells from OAmeniscus
secreted a mean 6 SD of 47.62 6 11.73 ng/ml of MIF,
which was not significantly different from cells isolated
from normal meniscus (31.656 5.54 ng/ml). MIF in
conditioned media from OA synovial fibroblasts was
not detectable (data not shown).
OA cartilage explants released a mean 6 SD of
167.9 6 55.92 pg MIF/ng DNA, which was significantly
higher (P5 0.0168) than that produced by normal cartilage
explants, which released a mean6 SD of 59.216 10.87 pg
MIF/ng DNA. MIF levels in human cartilage were visual-
ized by immunostaining. MIF was localized to chondro-
cytes in sections from both normal donors (Figure 1C) and
OA donors (Figure 1D) without significant differences in
immunopositivity, suggesting that the differences noted in
cultured cells and explants were due to differences in MIF
release into themedia.
Reduced severity of naturally occurring OA
with age in mice with MIF deletion. In order to deter-
mine if MIF contributes to the development of OA in vivo,
the knee joints from 12-month-old and 22-month-old male
MIF2/2 and wild-type mice were analyzed for OA severity.
Histologic evaluation of H&E-stained sections revealed
characteristic OA changes in the joints of the wild-type
mice at both ages, including degradation and loss of the
articular cartilage, thickening of the subchondral bone, and
osteophyte formation (Figure 2A). In contrast, the joints of
the MIF2/2mice displayed more healthy appearing articu-
lar cartilage, normal thickness of the subchondral bone,
and no osteophyte formation. Anti-MIF immunostaining
in a wild-type mouse section showedMIF expression in the
meniscus and the articular cartilage (Figure 2A). As
expected, there was a lack of staining for MIF in the sec-
tions fromMIF2/2mice.
OA severity, graded using theACS score, was signif-
icantly higher in the wild-type relative to the MIF2/2 mice
at both 12 and 22 months of age (Figure 2B). Wild-type
mice at 12 and 22 months developed significantly larger
osteophytes than the MIF2/2 mice (Figure 2C). The joints
of the 12-month-old and 22-month-old MIF2/2 and wild-
type mice were further evaluated using histomorphometric
analysis (Table 1). In both age groups, the MIF2/2 mice
maintained significantly greater articular cartilage area and
thickness and more viable chondrocytes than the wild-type
mice. Subchondral bone changes were also evident between
the genotypes. The subchondral bone area and thickness
were significantly greater in wild-type mice than in MIF2/2
mice. The only 2 parameters that were not significantly dif-
ferent between MIF2/2 and wild-type mice were the area
of chondrocyte necrosis and the calcified cartilage area.
Synovitis with synovial hyperplasia is another charac-
teristic ofOA. S100A8 is an alarmin protein that is produced
by synovial cells as well as activated macrophages and has
Figure 1. Macrophage migration inhibitory factor (MIF) levels in conditioned media from normal and osteoarthritic (OA) human chondrocyte
and meniscal cell cultures and in normal and OA human cartilage sections. A, MIF levels in normal and OA chondrocytes and meniscal cells.
Serum-free medium was collected after 16 hours of culture from unstimulated confluent monolayers of normal and OA chondrocytes and menis-
cal cells. MIF protein in media was measured by human MIF enzyme-linked immunosorbent assay (ELISA). Circles represent individual sam-
ples; horizontal lines show the mean (n5 12 donors for normal chondrocytes, 9 donors for OA chondrocytes, 8 donors for normal meniscus, and
9 donors for OA meniscus). P values were determined by unpaired t-test. B, MIF levels in normal and OA cartilage. Serum-free conditioned
medium was collected after 48 hours of culture from unstimulated normal and OA cartilage explants. MIF protein in media was measured by
human MIF ELISA and was normalized to the DNA content of the explants. Circles represent individual samples; horizontal lines show the
mean (n5 16 donors for normal cartilage explants and 7 donors for OA cartilage explants). P values were determined by unpaired t-test. No out-
liers were identified by the Grubbs outlier test. C and D, Immunohistochemistry results for MIF in sections of normal (C) and OA (D) human
knee cartilage.
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been shown to correlate with synovitis (27,30). Here, immu-
nohistochemistry was performed using anti-S100A8 on coro-
nal sections from 12-month-old and 22-month-old wild-type
and MIF2/2 mice (representative images are shown in
Figures 3A and B). In both genotypes, immunopositivity
was evident throughout the joint—in the articular carti-
lage, the meniscus, and the synovium. Specifically in the
wild-type mouse joints, S100A8 immunopositivity was
strong in both the cells and matrix of the synovium. As
shown in Figure 3A, S100A8 immunopositivity correlated
with areas of synovial hyperplasia and thickening of the
synovial lining. In contrast, S100A8 synovial immunostain-
ing revealed minimal synovial hyperplasia in the MIF2/2
mice. Based on the synovial scoring system described
above, there was no difference in synovial hyperplasia
between the 12-month-old wild-type and MIF2/2 mice,
while the 22-month-old wild-type mice exhibited more
severe synovial hyperplasia than the 22-month-old MIF2/2
Table 1. Histomorphometric analysis of aged mice with macrophage migration inhibitory factor deletion and wild-type
controls*









(n5 14) P† P‡
Articular cartilage area, mm2 0.0646 0.011 0.0406 0.016 ,0.001 0.0646 0.008 0.0296 0.018 ,0.001 0.089
Articular cartilage thickness, mm 0.0726 0.013 0.0436 0.017 ,0.001 0.0786 0.009 0.0376 0.019 ,0.001 0.339
Subchondral bone area, mm2 0.0806 0.016 0.1566 0.069 0.002 0.0706 0.025 0.1036 0.038 0.009 0.024
Subchondral bone thickness, mm 0.0596 0.011 0.1046 0.046 0.004 0.0706 0.023 0.1006 0.037 0.013 0.772
Number of viable chondrocytes 138.396 16.15 74.316 41.38 ,0.001 115.506 21.98 64.146 45.24 0.001 0.549
Area of chondrocyte necrosis, mm2 0.0086 0.006 0.0066 0.004 0.396 0.0086 0.011 0.0076 0.008 0.859 0.602
Calcified cartilage area, mm2 0.0636 0.012 0.0596 0.019 0.504 0.0496 0.005 0.0536 0.019 0.368 0.421
* Values are the mean6 SD. Histomorphometric measurements of cartilage and bone parameters in the medial tibial com-
partment of mid-coronal mouse knee sections were analyzed using the Osteomeasure Histomorphometry Program
(OsteoMetrics).
† By heteroscedastic t-test using SPSS.
‡ Twelve-month-old wild-type mice versus 22-month-old wild-type mice, by heteroscedastic t-test using SPSS.
Figure 2. Mice with macrophage migration inhibitory factor (MIF) deletion are protected against age-related osteoarthritis (OA). A, Represen-
tative histologic images of knee joint sections in 12-month-old MIF2/2 and wild-type (WT) mice. i, Hematoxylin and eosin (H&E)–stained sec-
tion of the medial tibial plateau of a wild-type mouse with an articular cartilage structure (ACS) score of 11. Arrow indicates degradation and
loss of articular cartilage; arrowhead indicates osteophyte formation; bracket indicates thickening of subchondral bone. ii, H&E-stained section
from an MIF2/2 mouse with an ACS score of 3. Bracket indicates normal subchondral bone thickness. iii, Wild-type mouse section
immunostained for MIF. Intracellular MIF is present in the meniscus (arrow) and articular cartilage (arrowhead). iv, MIF2/2 mouse section
immunostained for MIF, showing a lack of MIF immunopositivity in the meniscus (arrow) and cartilage (arrowhead). B and C, ACS score (B)
and osteophyte (OP) score (C) in MIF2/2 and wild-type mice. The medial tibial plateau of mid-coronal knee sections was scored using the ACS
score. Osteophyte scores are the sum of the scores for the medial tibial plateau and the medial femoral condyle. Symbols represent individual
mice; horizontal lines show the mean (n5 13 12-month-old wild-type mice, 13 12-month-old MIF2/2 mice, 14 22-month-old wild-type mice, and
16 22-month-old MIF2/2 mice). P values were determined by Kruskal-Wallis nonparametric one-way analysis of variance followed by Dunn’s
multiple comparison test.
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mice (Figure 3C). Additionally, the severity of synovial
hyperplasia increased between 12 and 22 months in the
wild-typemice.
Early bone differences in mice with MIF deletion
are notmaintained with age. Because of conflicting reports
of bone density differences in MIF2/2 mice compared to
wild-type mice (31,32) and the possibility that bone density
differences could influence the development of OA (33), we
measured trabecular bone parameters bymicro-CT scans of
the proximal metaphysis of the tibia from 8-week-old and
12-month-old male MIF2/2 and wild-type mice. The 8-
week-old male MIF2/2 mice had significantly greater bone
Figure 4. Micro–computed tomography analysis of 8-week-old and 12-month-old male mice with macrophage migration inhibitory factor (MIF)
deletion and wild-type (WT) controls. Bone density parameters in the proximal metaphysis of the tibia were analyzed using Scanco software. A,
Bone volume/total volume (BV/TV). B, Tissue mineral density. HA5 hydroxyapatite. C, Connectivity density. D, Trabecular number. E, Trabec-
ular separation. F, Trabecular thickness. Symbols represent individual mice; horizontal lines show the mean (n5 3 8-week-old wild-type mice, 3
8-week-old MIF2/2 mice, 4 12-month-old wild-type mice, and 5 12-month-old MIF2/2 mice). P values were determined by two-way analysis of
variance followed by Tukey’s multiple comparison post hoc test.
Figure 3. Reduced severity of synovial hyperplasia in 22-month-old mice with macrophage migration inhibitory factor (MIF) deletion. A and B,
Immunohistochemistry results for S100A8 in sections from a 22-month-old wild-type (WT) mouse with an articular cartilage structure (ACS)
score of 11 (A) and a 22-month-old MIF2/2 mouse with an ACS score of 0 (B). Representative histologic images are shown. Arrows indicate
regions of strong synovial S100A8 immunopositivity and synovial hyperplasia. M5meniscus. C, Sum of the synovial hyperplasia scores of the
medial and lateral compartments in wild-type and MIF2/2 mice. Symbols represent individual mice; horizontal lines show the mean (n5 5 12-
month-old wild-type mice, 5 12-month-old MIF2/2 mice, 11 22-month-old wild-type mice, and 9 22-month-old MIF2/2 mice). P values were
determined by Kruskal-Wallis nonparametric one-way analysis of variance followed by Dunn’s multiple comparison test.
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volume fraction (Figure 4A), tissue mineral density (Figure
4B), and connectivity density (Figure 4C) than the age-
matched wild-type mice. These differences were not main-
tained with age, as there were no significant differences in
any bone parameters between 12-month-old male MIF2/2
and wild-type mice. Bone density parameters were also
measured in female mice of the same ages, but there were
no differences in these parameters between MIF2/2 and
wild-typemice in either age group (data not shown).
MIFdeletion or treatment with anMIF-neutralizing
antibody does not reduce the severity of surgically induced
OA in young adult mice. We next wanted to determine if
MIF was required for the development of surgically
inducedOA in young adult mice.We used theDMMsurgi-
cal model to induce OA in 12-week-old male MIF2/2 and
wild-type mice and evaluated the severity of cartilage
lesions 10 weeks after surgery. Compared to the sham-
operated controls, both the wild-type mice and MIF2/2
mice developed significant cartilage lesions; however, in
contrast to the data on natural age-related OA, there was
no difference in severity between the 2 groups (Figure 5A).
Both the wild-type mice and MIF2/2 mice subjected to
DMM developed significantly larger osteophytes than the
sham-operated mice, but there was no difference between
the 2 groups (Figure 5B).
We also determined if inhibition of MIF systemi-
cally, using a neutralizing antibody, would alter the sever-
ity of surgically induced OA. Twelve-week-old male
C57BL/6 mice underwent the DMM procedure and were
then treated for 10 weeks with either an MIF-neutralizing
antibody or an IgG control antibody. The dose of anti-
MIF used here was sufficient to inhibit MIF activity in a
previous study (24). OA severity was analyzed 10 weeks
after surgery (Figure 5C). Due to limitations in the
amount of MIF antibody available and our previous data
indicating that a sham-operated control group did not
develop OA changes, the contralateral legs were scored as
the control group in this study. The limbs of the mice in
the control IgG-treated group and the anti-MIF–treated
group subjected to DMM developed significantly more
severe OA than the contralateral limbs, and there was no
difference in OA severity between the 2 treatment groups.
The limbs of the mice in both the IgG and MIF treatment
groups subjected to DMM developed significantly larger
osteophytes than the contralateral limbs (Figure 5D).
DISCUSSION
Although OA is characterized by common patho-
logic changes within affected joints, the pathways that lead
to OA can vary depending on the inciting factors. In this
study, we demonstrated that deletion of the proinflamma-
tory cytokine MIF protects mice against developing natu-
rally occurring age-related OA but not against developing
injury-induced OA. These findings are in stark contrast to
previous studies of mice with deletion of the proinflamma-
tory cytokine IL-6, where age-related OA was more severe
in the IL-6–knockout mice (34), while they were protected
against injury-induced OA in the same DMM model used
in the present study (35). Other studies have also shown
Figure 5. Inhibition of macrophage migration inhibitory factor (MIF) activity either by gene deletion or by neutralizing antibody does not pro-
tect young adult mice against injury-induced osteoarthritis (OA). A and B, Saf-O score, indicating OA severity 10 weeks after surgery (A) and
sum of the osteophyte (OP) scores in the medial tibial plateau and medial femoral condyle (B) in 12-week-old wild-type (WT) and MIF2/2 mice
subjected to either destabilization of the medial meniscus (DMM) or sham surgery. Symbols represent individual mice; horizontal lines show the
mean (n5 14 MIF2/2 mice with DMM, 16 sham-operated MIF2/2 mice, 16 wild-type mice with DMM, and 13 sham-operated wild-type mice).
C and D, Saf-O score, indicating OA severity 10 weeks after surgery (C) and sum of the osteophyte scores in the medial tibial plateau and
medial femoral condyle (D) in 12-week-old wild-type mice subjected to DMM and treated for 10 weeks with either MIF-neutralizing antibody
(anti-MIF) or IgG control antibody. The contralateral limb was used as the unoperated control. Symbols represent individual mouse limbs; hori-
zontal lines show the mean (n5 15 limbs with DMM from mice treated with anti-MIF, 15 contralateral control limbs from mice treated with
anti-MIF, 14 limbs with DMM from mice treated with IgG, and 14 contralateral control limbs from mice treated with IgG). P values were deter-
mined by Kruskal-Wallis nonparametric one-way analysis of variance followed by Dunn’s multiple comparison test.
358 ROWE ET AL
different effects when age-related and injury-induced OA
were evaluated in mice with specific gene deletions,
including MMP-3 deletion which, similar to our findings,
resulted in less severe age-related OA but had no effect
on OA severity in an injury model (for review, see ref. 36).
These studies emphasize the need to consider more than
one model of OA when determining the role of a particu-
lar factor and indicate that the successful treatment of
age-related OA and posttraumatic OA may require differ-
ent targets.
The aged MIF-knockout mouse not only exhibited
less articular cartilage damage compared to age-matched
wild-type mice but also less synovial hyperplasia and fewer
OA bone changes, including osteophytes. Synovial inflam-
mation is evident in.60% of clinical cases of OA as mea-
sured by magnetic resonance imaging (37). Synovial
inflammation is a key source of pain in OA due to macro-
phage infiltration and increased vascularization and inner-
vation of the synovium (38). We used the alarmin S100A8
as a marker of synovial changes due to its strong correla-
tion with synovial hyperplasia and synovitis as well as its
association with macrophage infiltration in the synovium
(27,30). However, while there is a clear correlation
between the MIF genotype, synovial hyperplasia, and OA
severity, it is difficult to determine if lack of MIF resulted
in less synovial involvement and this contributed to carti-
lage protection or if less cartilage damage in the MIF2/2
mice resulted in less synovial hyperplasia.
The DMM model effectively induces OA changes
in the cartilage and bone, but minimal synovitis has been
observed in this model (39). We also did not observe sig-
nificant synovitis or synovial hyperplasia in mice subjected
to DMM (data not shown), suggesting that the differential
effect of MIF-knockout on age-related OA and DMM-
induced OA may be due to a differential role of the syno-
vium. This would be consistent with studies that have
shown that MIF contributes to synovitis in models of
inflammatory arthritis (40). Since MIF is constitutively
expressed in the joint, it is possible that it exerts an age-
related deleterious action on joint homeostasis but is not
important in the acute setting of joint injury when the
expression of other inflammatory mediators prevails.
The finding that the ACS scores in the wild-type
mice did not change significantly between 12 and 22
months was unexpected. Since this was a cross-sectional
study, it is not possible to determine if this was due to a
lack of progression of the cartilage changes or just a
chance occurrence in two different sets of mice. However,
we did note that there was a significant decrease in the
subchondral bone area between the 12-month-old and 22-
month-old wild-type mice, and there was a trend toward a
significant decrease in the articular cartilage area between
the 2 groups, but we did not note differences in the num-
ber of viable chondrocytes or in the area of chondrocyte
necrosis. These aging changes in the mice are similar to
aging changes in humans where there is a thinning of the
articular cartilage (2), a decrease in the number of viable
chondrocytes (41), and an overall increase in bone turn-
over (1).
There is some controversy over the role of
MIF in bone. Studies have shown that MIF inhibits
osteoclastogenesis through activation of the tyrosine kinase
Lyn (42), and that MIF2/2mice have significantly less bone
volume than wild-type mice (32). Alternatively, MIF has
been shown to be necessary for osteoclastogenesis in a
mouse model of RA, and MIF2/2 mice were protected
against development of bone erosions in this model (15).
Because increased bone density has been shown to be a
potential risk factor for incident OA, while increased bone
turnover may promote progression (43,44), we examined
bone density in young and older adult MIF2/2 mice. We
found that the bone volume fraction and other bone param-
eters were higher in youngMIF2/2mice compared to wild-
type mice, but these early bone differences were not main-
tained with age. Therefore, it is unlikely that these early
bone density differences were responsible for the reduced
OA severity seen in the older adultMIF2/2mice.
It is not clear from the present study if MIF dele-
tion had a direct effect on the articular chondrocytes
that could explain less severe age-related OA. Immuno-
histochemistry results revealed that chondrocytes, as
well as meniscal cells, were immunopositive for MIF
and released MIF into the media when cultured. Similar
intracellular staining and release has been seen with
other cell types such as macrophages (12) and RA syno-
vial fibroblasts (14). Chondrocytes, but not meniscal
cells, from OA joints secreted more MIF than cells from
normal joints. However, we could not detect an effect of
extracellular MIF on joint tissue cells. We performed a
series of in vitro studies using recombinant MIF in doses
of up to 1 mg/ml and could not detect an increase in
ERK, p38, or JNK MAP kinase activation or increase in
MMP production in cultures of human chondrocytes,
meniscal cells, or synovial fibroblasts (see Supplemen-
tary Figure 1, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39844/abstract).
These in vitro results in joint tissue cells are con-
trary to the findings of published studies with other cell
types that showed recombinant MIF–stimulated phos-
phorylation of the ERK MAP kinase in Raji cells (a B
cell line) (9) and in primary rat osteoblasts (45). Addi-
tional published studies show recombinant MIF-
stimulated production of MMP-1 and MMP-3 in
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synovial fibroblasts isolated from OA and RA patients
(13) as well as MMP-9 and MMP-13 production in pri-
mary rat osteoblasts (45). However, those studies
required doses of MIF of up to 10 mg/ml to detect a
response, which far exceeds the amount of MIF mea-
sured in synovial fluid, which ranges from 3 to 19 ng/ml
(14,18), or the amount of MIF we measured in condi-
tioned media from confluent chondrocyte and meniscal
cell monolayers, which ranged from 1 to 140 ng/ml. We
examined chondrocytes for the presence of CD74, which
is the primary receptor for MIF, but could not detect
significant levels on the cell surface by flow cytometry
(Rowe MA, et al: unpublished observations).
These findings suggest that chondrocytes produce
and secrete MIF but that it does not have an autocrine
effect on cartilage. MIF may instead promote OA by pro-
moting macrophage infiltration into the joint, which
would explain the reduced synovial hyperplasia observed
in the aged mice with MIF deleted. MIF also has been
described to exert intracellular functions by intracytoplas-
mic interaction with the COP9 signalosome that influ-
ences cell cycle progression (46). Accordingly, the
distinction we observed between the effects of MIF dele-
tion versus immunoneutralization may be accounted for
by a strictly intracellular role for MIF in chondrocytes.
Taken together, our findings indicate that the lack
of MIF has a strong protective effect on naturally occur-
ring age-related OA. As the percentage of adults older
than 65 continues to increase, the prevalence of aging-
related diseases, including OA, is also increasing (47).
MIF is encoded in a functionally polymorphic locus that
occurs commonly in the population (48), and our data
prompt investigation into the potential role of variant MIF
alleles in OA incidence or progression. Therapies that are
able to stop or slow the progression of diseases of aging
are necessary in order to improve the quality of life and to
extend the healthy lifespan of the aging population.
ACKNOWLEDGMENTS
We thank the Gift of Hope Tissue and Organ Donor
Network, Dr. Susan Chubinskaya, and the donor families for
providing normal donor tissue. We also thank the Department
of Orthopaedic Surgery at Wake Forest Baptist Health and the
University of North Carolina for providing osteoarthritic tissue.
We thank Dr. Tom Smith (Department of Orthopaedic Sur-
gery, Wake Forest School of Medicine) and Kathryn Kelley
(Thurston Arthritis Research Center, University of North
Carolina at Chapel Hill) for their assistance in performing the
DMM surgeries, as well as Melissa Roy, Dr. Alexandra
Armstrong, and Dr. Laura Pritzker (University of Minnesota)
for their assistance with histologic grading/morphometry and
Dr. Ted Bateman and Eric Livingston (University of North
Carolina at Chapel Hill) for their assistance with the microCT.
We also thank Dr. Martin Lotz (Scripps Research Institute, La
Jolla, CA) for his kind gift of the human cartilage sections, Dr.
Peter van der Kraan (Radboud University Medical Center,
Nijmegen, The Netherlands) for his advice regarding our syno-
vial studies, and Dr. Johannes Roth (Institute of Immunology,
University of Munster, Munster, Germany) for his kind gift of
the S100A8 antibody.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Loeser had full access to all of
the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Study conception and design. Rowe, Lau, Carlson, Miller, Loeser.
Acquisition of data. Rowe, Harper, Lau, Carlson, Leng, Loeser.
Analysis and interpretation of data. Rowe, McNulty, Lau, Carlson,
Leng, Bucala, Loeser.
REFERENCES
1. Loeser RF. Age-related changes in the musculoskeletal system
and the development of osteoarthritis. Clin Geriatr Med 2010;
26:371–86.
2. Ding C, Cicuttini F, Scott F, Cooley H, Jones G. Association
between age and knee structural change: a cross sectional MRI
based study. Ann Rheum Dis 2005;64:549–55.
3. Chen AC, Temple MM, Ng DM, Verzijl N, DeGroot J,
TeKoppele JM, et al. Induction of advanced glycation end prod-
ucts and alterations of the tensile properties of articular carti-
lage. Arthritis Rheum 2002;46:3212–7.
4. Loeser RF, Gandhi U, Long DL, Yin W, Chubinskaya S. Aging
and oxidative stress reduce the response of human articular
chondrocytes to insulin-like growth factor 1 and osteogenic pro-
tein 1. Arthritis Rheumatol 2014;66:2201–9.
5. Messai H, Duchossoy Y, Khatib AM, Panasyuk A, Mitrovic DR.
Articular chondrocytes from aging rats respond poorly to
insulin-like growth factor-1: an altered signaling pathway. Mech
Ageing Dev 2000;115:21–37.
6. Blaney Davidson EN, Scharstuhl A, Vitters EL, van der Kraan
PM, van den Berg WB. Reduced transforming growth factor-b
signaling in cartilage of old mice: role in impaired repair capac-
ity. Arthritis Res Ther 2005;7:R1338–47.
7. Bobacz K, Gruber R, Soleiman A, Erlacher L, Smolen JS,
Graninger WB. Expression of bone morphogenetic protein 6 in
healthy and osteoarthritic human articular chondrocytes and
stimulation of matrix synthesis in vitro. Arthritis Rheum 2003;48:
2501–8.
8. Greene MA, Loeser RF. Aging-related inflammation in osteoar-
thritis. Osteoarthritis Cartilage 2015;23:1966–71.
9. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al.
MIF signal transduction initiated by binding to CD74. J Exp
Med 2003;197:1467–76.
10. Rajasekaran D, Zierow S, Syed M, Bucala R, Bhandari V, Lolis
EJ. Targeting distinct tautomerase sites of D-DT and MIF with
a single molecule for inhibition of neutrophil lung recruitment.
FASEB J 2014;28:4961–71.
11. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J,
David J, et al. Macrophage migration inhibitory factor (MIF)
sustains macrophage proinflammatory function by inhibiting p53:
regulatory role in the innate immune response. Proc Natl Acad
Sci U S A 2002;99:345–50.
12. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage
is an important and previously unrecognized source of macrophage
migration inhibitory factor. J Exp Med 1994;179:1895–902.
360 ROWE ET AL
13. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M,
Nishihira J. Macrophage migration inhibitory factor up-regulates
expression of matrix metalloproteinases in synovial fibroblasts of
rheumatoid arthritis. J Biol Chem 2000;275:444–50.
14. Onodera S, Tanji H, Suzuki K, Kaneda K, Mizue Y, Sagawa A,
et al. High expression of macrophage migration inhibitory factor in
the synovial tissues of rheumatoid joints. Cytokine 1999;11:163–7.
15. Gu R, Santos LL, Ngo D, Fan H, Singh PP, Fingerle-Rowson
G, et al. Macrophage migration inhibitory factor is essential for
osteoclastogenic mechanisms in vitro and in vivo mouse model
of arthritis. Cytokine 2015;72:135–45.
16. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand
EF. Macrophage migration inhibitory factor in systemic lupus
erythematosus. J Rheumatol 2004;31:268–73.
17. Hoi AY, Hickey MJ, Hall P, Yamana J, O’Sullivan KM, Santos
LL, et al. Macrophage migration inhibitory factor deficiency
attenuates macrophage recruitment, glomerulonephritis, and
lethality in MRL/lpr mice. J Immunol 2006;177:5687–96.
18. Liu M, Hu C. Association of MIF in serum and synovial fluid
with severity of knee osteoarthritis. Clin Biochem 2012;45:737–9.
19. Harper JM, Wilkinson JE, Miller RA. Macrophage migration
inhibitory factor-knockout mice are long lived and respond to
caloric restriction. FASEB J 2010;24:2436–42.
20. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A,
Koenen RR, et al. MIF is a noncognate ligand of CXC chemo-
kine receptors in inflammatory and atherogenic cell recruitment.
Nat Med 2007;13:587–96.
21. Loeser RF, Pacione CA, Chubinskaya S. The combination of
insulin-like growth factor 1 and osteogenic protein 1 promotes
increased survival of and matrix synthesis by normal and osteo-
arthritic human articular chondrocytes. Arthritis Rheumatol
2003;48:2188–96.
22. Yin W, Park JI, Loeser RF. Oxidative stress inhibits insulin-like
growth factor-I induction of chondrocyte proteoglycan synthesis
through differential regulation of phosphatidylinositol 3-Kinase-
Akt and MEK-ERK MAPK signaling pathways. J Biol Chem
2009;284:31972–31981.
23. Loeser RF, Olex AL, McNulty MA, Carlson CS, Callahan MF,
Ferguson CM, et al. Microarray analysis reveals age-related dif-
ferences in gene expression during the development of osteoar-
thritis in mice. Arthritis Rheum 2012;64:705–17.
24. Leng L, Chen L, Fan J, Greven D, Arjona A, Du X, et al. A
small-molecule macrophage migration inhibitory factor antago-
nist protects against glomerulonephritis in lupus-prone NZB/
NZW F1 and MRL/lpr mice. J Immunol 2011;186:527–38.
25. McNulty MA, Loeser RF, Davey C, Callahan MF, Ferguson
CM, Carlson CS. A comprehensive histological assessment of
osteoarthritis lesions in mice. Cartilage 2011;2:354–63.
26. Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ,
et al. CCR2 chemokine receptor signaling mediates pain in experi-
mental osteoarthritis. Proc Natl Acad Sci U S A 2012;109:20602–7.
27. Schelbergen RF, de Munter W, van den Bosch MH, Lafeber FP,
Sloetjes A, Vogl T, et al. Alarmins S100A8/S100A9 aggravate
osteophyte formation in experimental osteoarthritis and predict
osteophyte progression in early human symptomatic osteoarthri-
tis. Ann Rheum Dis 2016;75:218–25.
28. Lau AG, Sun J, Hannah WB, Livingston EW, Heymann D,
Bateman TA, et al. Joint bleeding in factor VIII deficient mice
causes an acute loss of trabecular bone and calcification of joint
soft tissues which is prevented with aggressive factor replace-
ment. Haemophilia 2014;20:716–22.
29. Muller R, van Campenhout H, van Damme B, van der Perre G,
Dequeker J, Hildebrand T, et al. Morphometric analysis of human
bone biopsies: a quantitative structural comparison of histological
sections and micro-computed tomography. Bone 1998;23:59–66.
30. Schelbergen RF, van Dalen S, ter Huurne M, Roth J, Vogl T,
Noel D, et al. Treatment efficacy of adipose-derived stem cells
in experimental osteoarthritis is driven by high synovial activa-
tion and reflected by S100A8/A9 serum levels. Osteoarthritis
Cartilage 2014;22:1158–66.
31. Oshima S, Onodera S, Amizuka N, Li M, Irie K, Watanabe S,
et al. Macrophage migration inhibitory factor-deficient mice are
resistant to ovariectomy-induced bone loss. FEBS Lett 2006;580:
1251–6.
32. Jacquin C, Koczon-Jaremko B, Aguila HL, Leng L, Bucala R,
Kuchel GA, et al. Macrophage migration inhibitory factor
inhibits osteoclastogenesis. Bone 2009;45:640–9.
33. Hardcastle SA, Dieppe P, Gregson CL, Davey Smith G, Tobias
JH. Osteoarthritis and bone mineral density: are strong bones
bad for joints? Bonekey Rep 2015;4:624.
34. De Hooge AS, van de Loo FA, Bennink MB, Arntz OJ, de
Hooge P, van den Berg WB. Male IL-6 gene knock out mice
developed more advanced osteoarthritis upon aging. Osteoarthri-
tis Cartilage 2005;13:66–73.
35. Ryu JH, Yang S, Shin Y, Rhee J, Chun CH, Chun JS. Interleu-
kin-6 plays an essential role in hypoxia-inducible factor 2a–
induced experimental osteoarthritic cartilage destruction in mice.
Arthritis Rheum 2011;63:2732–43.
36. Little CB, Zaki S. What constitutes an “animal model of
osteoarthritis” – the need for consensus? Osteoarthritis Cartilage
2012;20:261–7.
37. Wang X, Jin X, Han W, Cao Y, Halliday A, Blizzard L, et al.
Cross-sectional and longitudinal associations between knee joint
effusion synovitis and knee pain in older adults. J Rheumatol
2016;43:121–30.
38. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB,
Bresnihan B. Synovial tissue inflammation in early and late oste-
oarthritis. Ann Rheum Dis 2005;64:1263–7.
39. Jackson MT, Moradi B, Zaki S, Smith MM, McCracken S,
Smith SM, et al. Depletion of protease-activated receptor 2 but
not protease-activated receptor 1 may confer protection against
osteoarthritis in mice through extracartilaginous mechanisms.
Arthritis Rheumatol 2014;66:3337–48.
40. Morand EF, Bucala R, Leech M. Macrophage migration inhibi-
tory factor: an emerging therapeutic target in rheumatoid arthri-
tis. Arthritis Rheum 2003;48:291–9.
41. Kuhn K, D’Lima DD, Hashimoto S, Lotz M. Cell death in carti-
lage. Osteoarthritis Cartilage 2004;12:1–16.
42. Mun SH, Oh D, Lee SK. Macrophage migration inhibitory fac-
tor down-regulates the RANKL–RANK signaling pathway by
activating Lyn tyrosine kinase in mouse models. Arthritis
Rheumatol 2014;66:2482–93.
43. Dequeker J, Aerssens J, Luyten FP. Osteoarthritis and osteopo-
rosis: clinical and research evidence of inverse relationship.
Aging Clin Exp Res 2003;15:426–39.
44. Zhang Y, Hannan MT, Chaisson CE, McAlindon TE, Evans
SR, Aliabadi P, et al. Bone mineral density and risk of incident
and progressive radiographic knee osteoarthritis in women: the
Framingham Study. J Rheumatol 2000;27:1032–7.
45. Onodera S, Nishihira J, Iwabuchi K, Koyama Y, Yoshida K, Tanaka
S, et al. Macrophage migration inhibitory factor up-regulates matrix
metalloproteinase-9 and -13 in rat osteoblasts: relevance to intracel-
lular signaling pathways. J Biol Chem 2002;277:7865–74.
46. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-
Kentischer A, Flieger O, et al. Intracellular action of the cyto-
kine MIF to modulate AP-1 activity and the cell cycle through
Jab1. Nature 2000;408:211–6.
47. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M,
et al. The global burden of hip and knee osteoarthritis: estimates
from the global burden of disease 2010 study. Ann Rheum Dis
2014;73:1323–30.
48. Bucala R. MIF, MIF alleles, and prospects for therapeutic inter-
vention in autoimmunity. J Clin Immunol 2013;33 Suppl 1:S72–8.
MIF DELETION REDUCES AGE-RELATED OA 361
